These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 10983783)

  • 1. Psychopharmacology and mental retardation: a 10 year review (1990-1999).
    Matson JL; Bamburg JW; Mayville EA; Pinkston J; Bielecki J; Kuhn D; Smalls Y; Logan JR
    Res Dev Disabil; 2000; 21(4):263-96. PubMed ID: 10983783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychopharmacology research for individuals with mental retardation: methodological issues and suggestions.
    Matson JL; Bielecki J; Mayville SB; Matson ML
    Res Dev Disabil; 2003; 24(3):149-57. PubMed ID: 12742384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of previously undiagnosed psychiatric disorders in persons with developmental disabilities decreased or eliminated self-injurious behavior.
    Tsiouris JA; Cohen IL; Patti PJ; Korosh WM
    J Clin Psychiatry; 2003 Sep; 64(9):1081-90. PubMed ID: 14628984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of Pro Re Nata or Statim medications for behavioral control: a summary of experience at a tertiary care children's mental health center.
    Swart GT; Siman E; Stewart SL
    J Child Adolesc Psychopharmacol; 2011 Feb; 21(1):67-77. PubMed ID: 21288118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The international consensus process on psychopharmacology and intellectual disability.
    Reiss S; Aman MG
    J Intellect Disabil Res; 1997 Dec; 41 ( Pt 6)():448-55. PubMed ID: 9430048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychotropic prescribing in people with intellectual disability and challenging behaviour.
    Sheehan R; Strydom A; Morant N; Pappa E; Hassiotis A
    BMJ; 2017 Aug; 358():j3896. PubMed ID: 28821479
    [No Abstract]   [Full Text] [Related]  

  • 7. Brief report: effects of clozapine on self-injurious behavior of two risperidone nonresponders with mental retardation.
    Hammock R; Levine WR; Schroeder SR
    J Autism Dev Disord; 2001 Feb; 31(1):109-13. PubMed ID: 11439749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial.
    Janowsky DS; Barnhill LJ; Davis JM
    J Clin Psychiatry; 2003 Oct; 64(10):1258-65. PubMed ID: 14658977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of psychotropic medications for persons with mental retardation who live in Oklahoma nursing homes.
    Spreat S; Conroy J
    Psychiatr Serv; 1998 Apr; 49(4):510-2. PubMed ID: 9550242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review.
    Deb S; Farmah BK; Arshad E; Deb T; Roy M; Unwin GL
    Res Dev Disabil; 2014 Mar; 35(3):711-25. PubMed ID: 24405794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brief report: clonazepam behavioral side effects with an individual with mental retardation.
    Kalachnik JE; Hanzel TE; Sevenich R; Harder SR
    J Autism Dev Disord; 2003 Jun; 33(3):349-54. PubMed ID: 12908837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychotropic drug prescribing in child and adolescent learning disability psychiatry.
    Bramble D
    J Psychopharmacol; 2007 Jul; 21(5):486-91. PubMed ID: 17446203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The association between psychiatric diagnoses and severe behavior problems in mental retardation.
    Rojahn J; Borthwick-Duffy SA; Jacobson JW
    Ann Clin Psychiatry; 1993 Sep; 5(3):163-70. PubMed ID: 7904216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and specificity of pharmacological therapies for behavioral disorders in persons with mental retardation.
    Baumeister AA; Todd ME; Sevin JA
    Clin Neuropharmacol; 1993 Aug; 16(4):271-94. PubMed ID: 8374912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychopharmacoepidemiology of mental retardation: 1966 to 1995.
    Singh NN; Ellis CR; Wechsler H
    J Child Adolesc Psychopharmacol; 1997; 7(4):255-66. PubMed ID: 9542696
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury.
    Luiselli JK; Blew P; Thibadeau S
    Behav Modif; 2001 Jan; 25(1):62-78. PubMed ID: 11151486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Soles of the Feet: a mindfulness-based self-control intervention for aggression by an individual with mild mental retardation and mental illness.
    Singh NN; Wahler RG; Adkins AD; Myers RE;
    Res Dev Disabil; 2003; 24(3):158-69. PubMed ID: 12742385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A guide to psychopharmacological treatment of patients with intellectual disability in psychiatry.
    Molina-Ruiz RM; Martín-Carballeda J; Asensio-Moreno I; Montañés-Rada F
    Int J Psychiatry Med; 2017 Mar; 52(2):176-189. PubMed ID: 28792289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of beta blockers in the management of problem behaviours in people with intellectual disabilities: a systematic review.
    Ward F; Tharian P; Roy M; Deb S; Unwin GL
    Res Dev Disabil; 2013 Dec; 34(12):4293-303. PubMed ID: 24171827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practitioner versus medication-expert opinion on psychiatric pharmacotherapy of mentally retarded patients with mental disorders.
    Patel NC; Crismon ML; Rush AJ; Frances A
    Am J Health Syst Pharm; 2001 Oct; 58(19):1824-9. PubMed ID: 11596698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.